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Abstract
Purpose To evaluate whether β-blockers were associated
with a reduction in cardiovascular events or angina after
Coronary Artery Bypass Graft (CABG) surgery, in otherwise
stable low-risk patients during a mid-term follow-up.
Methods We performed a post-hoc analysis of the IMAGINE
(Ischemia Management with Accupril post–bypass Graft via
Inhibition of angiotensin coNverting Enzyme) trial, which tested
the effect of Quinapril in 2553 hemodynamically stable patients
with left ventricular ejection fraction (LVEF) >40%, after sched-
uled CABG. The association betweenβ-blocker therapy and the
incidence of cardiovascular events (death, cardiac arrest, myo-
cardial infarction, revascularizations, angina requiring hospitali-
zation, stroke or hospitalization for heart failure) or angina that
was documented to be due to underlying ischemia was tested
with Cox regression and propensity adjusted analyses.
Results In total, 1709 patients (76.5 %) were using a β-
blocker. Patients had excellent control of risk factors;
with mean systolic blood pressure being 121±14
mmHg, mean LDL cholesterol of 2.8mmol/l, 59% of
patients received statins and 92% of patients received
antiplatelet therapy. During a median follow-up of 33
months, β-blocker therapy was not associated with a
reduction in cardiovascular events (hazard ratio 0.97;
95 % confidence interval 0.74–1.27), documented angi-
na (hazard ratio 0.85; 95 % confidence interval 0.61–
1.19) or any of the individual components of the com-
bined endpoint. There were no relevant interactions for
demographics, comorbidities or surgical characteristics.
Propensity matched and time-dependent analyses re-
vealed similar results.
Conclusions β-blocker therapy after CABG is not associated
with reductions in angina or cardiovascular events in low-risk
patients with preserved LVEF, and may not be systematically
indicated in such patients.
Keywords Coronary artery disease .Myocardial ischemia .
Coronary artery bypass . Myocardial revascularization .
Adrenergic beta-Antagonists
Introduction
Beta adrenoreceptor blockers (β-blockers) are among the
most commonly prescribed cardiovascular drugs that are used
to treat hypertension, arrhythmias, coronary artery disease
(CAD) and heart failure. In patients with stable CAD, β-
blockers are recommended as first line therapy based on their
potent anti-anginal effects and on extrapolation of the prog-
nostic benefits that has been demonstrated after myocardial
infarction (MI) and in patients with heart failure [1, 2].
Most of the studies supporting the efficacy of β-blockers in
patients with CAD predate the current era of coronary
revascularisation, more intense anti-platelet therapy, the use of
statins and more stringent blood pressure goals and were
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specifically designed to evaluate their effects on angina.
While β-blockers are often continued in patients after
coronary artery bypass grafting (CABG) surgery, even in
patients with preserved left ventricular (LV) function, ev-
idence for their efficacy in this setting is sparse [1, 3, 4].
This issue is particularly relevant since β-blockers may
cause counterproductive side effects such as new onset
diabetes and dyslipidemia [5, 6].
We therefore aimed to evaluate whether β-blocker therapy
was associated with a reduced incidence of angina or cardio-
vascular events when continued after CABG. Therefore, we
performed a post-hoc analysis of the IMAGINE (Ischaemia
Management with Accupril post-bypass Graft via Inhibition
of angiotensin coNverting Enzyme) trial database which com-
prised of low-risk patients with normal cardiac function, ran-
domized to quinapril or placebo early after elective CABG
surgery.
Methods
A detailed description of the IMAGINE-trial protocol has
been published previously [7]. In brief, it was a double-
blinded, placebo-controlled, randomized, international,
multicentre trial that tested whether the ACE-inhibitor
quinapril when compared to placebo reduced symptoms of
angina or cardiovascular events in patients with preserved
LV function post-CABG surgery during a mid-term follow-
up for a maximum of 43 months. Patients were included be-
tween November 1999 and September 2004. Written in-
formed consent was obtained from all patients. The study
was in compliance with the Declaration of Helsinki and the
ethics committees from all participating institutions provided
approval of the research protocol. In this trial, ACE-inhibition
with quinapril did not improve outcome when started early
after CABG in low-risk patients with preserved LV function,
while adverse events were increased with quinapril during the
first 3 months after randomization.
Patients
In total, 2553 patients were randomized to quinapril or place-
bo within 7 days after scheduled CABG, except in France
where randomization was possible until 10 days post-
CABG. If tolerated, the ACE inhibitor quinapril was uptitrated
to 40 mg daily or its placebo equivalent. Patients were eligible
for participation when hemodynamically stable and if left ven-
tricular ejection fraction (LVEF) was >40 %. Serum creatinine
>2.26 mg/dL (200 μmol/L) was an exclusion criterium as
were suspicion of renal artery stenosis, a single kidney or a
transplanted kidney. During the study, type II diabetes with
microalbinuria and insulin-dependent diabetes became
exclusion criteria due to increasing evidence of benefit of
ACE inhibitors in these patients.
β-blocker Treatment
Of the 2553 patients included in the IMAGINE trial, 320
patients were using sotalol. Because sotalol has class 3 anti-
arrhythmic effects which may modulate event rate through
pro-arrythmic effects, patients using sotalol were excluded
from this analysis. Thus, 2233 patients were available for
analysis. Patients were divided in two groups, according to
β-blocker therapy.β-blocker dose was expressed as a percent-
age of the maximum recommended dose. For the time-
dependent analysis β-blocker use was scored at randomiza-
tion, 50, 90 days, 1, 2 and 3 years after randomization.
Endpoints
The primary IMAGINE endpoint consisted of the composite
of cardiovascular death, resuscitated cardiac arrest, nonfatal
MI, coronary revascularization, unstable angina requiring hos-
pitalization, documented angina not requiring hospitalization,
congestive heart failure which required hospitalization and
stroke. The secondary IMAGINE endpoint consisted of the
primary endpoint with the addition of transient ischemic at-
tack and other cardiovascular events requiring hospitalization.
One of the unique features of the IMAGINE trial was the
meticulous verification of myocardial ischemia in patients
with suspected recurrence of angina. An episode of angina
was considered valid if typical symptoms of angina were as-
sociated with one of the following conditions: temporary ST
deviations on electrocardiogram; a stress test with reversible
wall motion abnormalities on echocardiography or reversible
nuclear scan defects; coronary angiography demonstrating
compatible lesions which could not be explained by incom-
plete revascularization or any episode of angina requiring hos-
pitalization. Finally, we defined major adverse cardiovascular
events (MACE) as the composite of angina, cardiovascular
death, resuscitated cardiac arrest, nonfatal MI and coronary
revascularization.
Statistical Analysis
The baseline characteristics were compared according to pres-
ence of β-blocker therapy using students T-, Mann–Whitney
U-, χ2- or Fisher exact tests, as appropriate. Time to first event
was calculated by the Kaplan–Meier method and displayed
graphically. Differences in event rate according to β-blocker
therapy were calculated from a Cox proportional hazards re-
gression model and expressed as an adjusted hazard ratio with
two-sided confidence interval of 95 %. Cox regression analy-
sis was adjusted for the effects of age, gender, ethnicity, his-
tory of MI, revascularization, non-cardiac vascular event,
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hypertension, diabetes, hypercholesterolemia, the number of
days after surgery that the patient was randomized, beating
heart surgery, nr of grafted vessels, complete revasculariza-
tion, LVEF and concomitant medication. Propensity matched
analysis was performed as a sensitivity analysis and as an
additional effort to adjust for residual confounding. We calcu-
lated a propensity score for β-blocker-use with multivariable
logistic regression, using all available variables. Covariates
were selected when associated with β-blocker therapy or
when they were independently associated with the outcome.
Patients were then matched based upon β-blocker treatment
and similar propensity score based on 1 to 1 nearest neighbor
matching without replacement. Pre-match imbalance and
post-match balance were estimated with standardized differ-
ences for each covariate. Since approximately 20-25 % of
patients switched groups (started or discontinued a β-
blocker) over time either permanent or temporary, we per-
formed an additional Cox proportional hazards regression
analysis with β-blocker as the time-dependent covariate.
The software packages used for these analyses were SPSS
20.0 and STATA (version 12.0).
Results
Baseline Characteristics
Of the 2233 patients analyzed, 1709 (76.5 %) used a β-
blocker. At 1 year, 1174 patients (62.0%) used a β-blocker
and 801 (58.9 %) 2 years after randomization. Average β-
blocker dose was 41.2, 41.8 and 40.9 % of the maximal rec-
ommended dose at these time points respectively. The maxi-
mal recommended dose was given in 128, 103 and 67 patients
respectively (7.5, 8.8 and 8.4% respectively). Baseline char-
acteristics are shown in Table 1. Overall, these were low-risk
patients with mean age of 61±10 years, mean LVEF 60±
10 %, low prevalence of diabetes (219 patients, 9.8 %), and
good renal function (eGFR 69±24ml/min/1,73 m2). Patients
treated with β-blockers had a history of hypertension more
often (50 % vs 42 %) while other medical history was com-
parable between groups. Mean arterial pressure, heart rate and
LVEF were also similar between groups. The majority of pa-
tients received statin therapy (53 and 60% for no β-blocker
and β-blocker patients respectively), while other lipid-
lowering therapy was given in 3 % of patients. Patients on
β-blocker therapy were more frequently receiving antiplatelet
therapy and statins, but less frequently using anti-arrhythmic
drugs or calcium channel blockers.
Mean LDL values were slightly higher at randomization in
patients withoutβ-blocker (3.0±1.0 vs 2.8±1.0, p=0.008) but
did not differ during follow-up (2.6±0.8 vs 2.6±0.8 mmol/l,
p=0.50 at 1 year follow-up and 2.5±0.8 vs 2.5±0.8 mmol/l,
p=0.72 at study closure). Mean systolic blood pressure was
121±14 mmHg and slightly lower in patients on β-blockers
at randomization, but it remained ≤131 mmHg with no sig-
nificant difference between groups throughout follow-up. In
the majority of patients (88 %) revascularization was com-
plete (defined as bypass of all stenosis of >70 % in vessels
with a diameter >1 mm). Surgical characteristics were
comparable.
Cox Regression Analysis
Out of the 2233 patients analysed, 299 (13.4 %) patients had
experienced a primary event, while 451 (20.2 %) patients had
experienced a secondary event during a median follow-up of
33 months (IQR 16–43). Total event count for MACE and
Angina was 245 (11.0 %) and 191 (8.6 %) respectively. β-
blocker treatment was not associated with a difference in cu-
mulative incidence of any of the composite endpoints (prima-
ry endpoint, secondary endpoint, MACE, angina, (Fig. 1)).
Multivariate regression did not reveal any association between
β-blocker treatment and the primary endpoint (hazard ratio
(HR) 0.97; 95 % confidence interval (CI) 0.74–1.27), docu-
mented angina (HR 0.85; 95%CI 0.61–1.19) or any of the
other composite endpoints and their individual components
(Fig. 2). The neutral effects of β-blocker therapy were consis-
tent among several relevant subgroups including age, gender,
hypertension, previous MI, completeness of revascularization
and treatment allocation (Fig. 3).
Propensity Matched and Time-Dependent Analysis
The propensity matched population consisted of 424 patients
per group. Absolute standardized differences for all baseline-
characteristics were <10 %, indicating an adequate match
(Fig 4a). There was no association between β-blocker therapy
and the occurrence of the primary IMAGINE endpoint when
adjusting for propensity score and its covariates in the un-
matched population nor when the propensity matched popula-
tion was considered separately (Figs. 4b and 5). Similar results
were obtained for the secondary endpoint, MACE and angina
(data not shown). To account for differences in treatment over
time, we analysed β-blocker therapy as a time-dependent co-
variate in our Cox-regression models. Again, no association
was found for β-blocker therapy and outcome (Fig. 5).
Discussion
β-blocker therapy has been the cornerstone of pharmacother-
apy of CAD for decades, but recent evidence suggests that this
central role may not be justified in patients that are at relatively
low risk, have good control of their cardiovascular risk factors
and are receiving evidence-based therapy [5, 8, 9]. In patients
receiving CABG, pre-operative β-blocker therapy has been
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reported to be as high as 80–93 % over the last few years [9].
However, it is unknown if β-blockers should be continued
after CABG. We therefore performed an explorative analysis
to determine if β-blocker therapy was associated with reduc-
tions in the incidence of angina or cardiovascular events after
CABG surgery in stable patients without heart failure or LV
dysfunction. Additionally, we investigated the incidence of
individual components of the composite outcome.
In our current retrospective analysis of low-risk patients,
we show that β-blockers were frequently continued after
CABG for a mid-term follow-up to 43 months. β-blocker
use was, however, not associated with a decreased risk of
recurrent angina or cardiovascular events, nor any of the indi-
vidual components of the composite outcomes. Our results
were consistent across different types of analyses, including
propensity matched and time-dependent analyses, suggesting
that the lack of association between β-blocker therapy and
clinical outcome is robust. This patient population was initial-
ly selected to test whether ACE-inhibition in patients with a
low event-rate would have additional benefit on top of stan-
dard medical therapy. This low event-rate did naturally reduce
the power of our analysis, but also indicates the potential
Table 1 Baseline characteristics
stratified for use of β-blocker at
randomization
Variable no β-blocker (n=524) β-blocker (n=1709) p-value
General characteristics
Age (yrs) 62±10 61±10 0.052
Male, n (%) 459 (88) 1495 (88) 1.000
Caucasian, n (%) 503 (96) 1645 (96) 0.169
Days post CABG 4.0±1.7 4.3±1.7 <0.001
Body mass index (kg/m2) 27.9±5.0 27.6±5.5 0.350
Medical history
Myocardial infarction, n (%) 213 (41) 668 (39) 0.540
Coronary revascularization, n (%) 105 (20) 19.4 (19) 0.753
Non-cardiac vascular event, n (%) 60 (12) 182 (11) 0.630
Diabetes, n (%) 50 (10) 169 (10) 0.867
Hypertension, n (%) 222 (42) 854 (50) 0.002
Hypercholesterolemia, n (%) 411 (78) 1343 (79) 0.951
Current smoker, n (%) 100 (19) 349 (20) 0.260
Surgical characteristics
Beating heart surgery, n (%) 90 (17) 318 (19) 0.478
Three vessel disease, n (%) 340 (65) 1090 (64) 0.845
Nr of anastomoses, n (%) 3.3±1.1 3.2±1.1 0.335
Complete revascularization, n (%) 470 (90) 1490 (87) 0.128
Hemodynamics
Systolic blood pressure (mmHg) 122±14 121±13 0.042
Diastolic blood pressure (mmHg) 70±9 70±9 0.257
LVEF (%) 60±10 60±10 0.830
Heart rate (bpm) 83±13 82±13 0.207
eGFR (ml/min/1,73 m2) 68±26 69±23 0.258
Medication
Quinapril, n (%) 263 (50) 856 (50) 1.000
Anti-arrhytmic drug, n (%) 87 (17) 134 (8) <0.001
Calcium-channel blocker, n (%) 198 (38) 372 (22) <0.001
Cardiac glycoside, n (%) 29 (6) 97 (6) 1.000
Diuretic, n (%) 175 (33) 589 (35) 0.674
Coumarine derivate, n (%) 49 (9) 70 (4) <0.001
Antiplatelet, n (%) 453 (87) 1610 (94) <0.001
Other lipid-lowering drugs, n (%) 11 (2) 46 (3) 0.528
Statin, n (%) 280 (53) 1032 (60) 0.005
Nitrate, n (%) 39 (7) 100 (6) 0.752
Values shown are means ± SD or n (%). CABG Coronary Artery Bypass Grafting, eGFR Estimated Glomerular
Filtration Rate, LVEF Left Ventricular Ejection Fraction
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benefit of β-blockers in this population is limited. While the
results may be different in the general CABG population, our
current data fuel the hypothesis that these agents should not be
continued indiscriminately.
β-blockers in Patients with CAD
β-blockers reduce heart rate, blood pressure and stroke vol-
ume, three key determinants of myocardial oxygen demand.
In addition, β-blockers increase coronary blood flow through
prolongation of the diastole. In concert, these mechanisms are
deemed responsible for the beneficial effects of β-blockers.
Indeed, several studies have convincingly demonstrated that
β-blockers reduce the burden of angina in patients with ob-
structive CAD [2, 10]. The prescription of β-blockers in pa-
tients with CAD is, however, more generally advocated based
on the extrapolation of prognostic benefit observed in patients
after MI and in heart failure patients [2]. Our study suggests
that in low-risk patients after CABG surgery, these extrapola-
tions may need additional investigation.
Fig. 1 Outcome according to β-blocker therapy – Cumulative event
rates for composite endpoints stratified for β-blocker therapy. Hazard
ratios are adjusted for age, gender, ethnicity, history of myocardial infarc-
tion, revascularization, non-cardiac vascular event, hypertension,
diabetes, hypercholesterolemia, days after CABG (coronary artery bypass
grafting), beating heart surgery, nr of vessel disease, complete revascular-
ization, left ventricular ejection fraction and concomitant medication.
MACE, Major Adverse Cardiovascular Event
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β-blocker Therapy After Revascularization
Several potential explanations may underlie the neutral
effects of β-blocker therapy in our population. First, most
patients were fully revascularized, thereby effectively re-
moving the substrate for angina and potentially for car-
diovascular events as well. Therefore the potential benefit
of β-blockers seems less relevant for the occurrence of
these events. Our findings are in line with an earlier study
which showed no benefit of metoprolol on exercise capac-
ity or myocardial ischemia in patients revascularized with
CABG [11].
Second, this study purposely selected CAD patients with
low risk for cardiovascular events. Indeed, cardiovascular mor-
tality was <1.4% over the median follow-up of 3 years, and the
incidence of MACE was only 9.4 %. This is similar to patient
populations with cardiovascular risk factors, but without
established CAD, underscoring the low incidence of cardiovas-
cular events in the present population [5, 12]. In fact, the re-
cently published Study assessInG the morbidity-mortality
beNefits of the If inhibitor ivabradine in patients with
coronarY artery disease (SIGNIFY) which randomized 19
102 patients with normal cardiac function to the selective sinus
node inhibitor ivabradine, failed to show a benefit on outcome
Fig. 2 Cox regression – Hazard
ratios and 95 % confidence
intervals for composite endpoints
and individual components after
adjustment for same variables as
in Fig. 1. MACE, Major Adverse
Cardiovascular Event
Fig. 3 Interaction analysis for β-
blocker – Hazard ratios for β-
blocker therapy in relevant
subgroups
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[13]. Heart rate reduction is considered to be themost important
mode of action of β-blockers in CAD. The neutral results of
SIGNIFY therefore provide an additional line of evidence
supporting the concept that modulation of the sympathetic tone
is not generally effective after revascularization in low-risk pa-
tients. Of note, patients using β-blockers have significantly
lower heart rates compared to the reference group. β-blockers
are particularly effective in patients with LV dysfunction [14],
which was previously common after MI. A recent study report-
ed a mean LVEF of 54.8 % in STEMI-patients who had re-
ceived primary percutaneous coronary intervention [15]. In an
analysis of contemporary patients with history of MI, β-
blockers were not associated with a reduction in cardiovascular
events [5]. Other studies only found a favorable association
between β-blockers and cardiovascular events in patients with
recent MI [16–18]. Together these findings suggest that the
protective effects of β-blockers are confined to patients with
a recent MI, ongoing myocardial ischemia or significant LV
dysfunction.
Clinical Implications
The results of this analysis of a low-risk population with nor-
mal cardiac function suggest that β-blockers do not have ad-
ditional beneficial effects after CABG. This has not been stud-
ied in a prospective randomized trial. Therefore, there are no
data supporting indiscriminate use of β-blockers in patients
who are asymptomatic, are receiving evidence-based therapy
Fig. 4 Propensity matched
analysis – (a) standardized
differences between baseline
characteristics before and after
matching. (b) Cumulative event
rate for the primary endpoint in
the propensity matched
population. CABG, Coronary
Artery Bypass Grafting; PCI,
Percutaneous Coronary
Intervention
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for CAD and with good LV function after successful revascu-
larization. This is reflected in the most recent AHA guidelines
for management of stable ischemic heart disease with a class
IIb recommendation for these patients [19]. The ESC guide-
lines do not mention a specific recommendation for β-blocker
use in these low-risk asymptomatic patients [1]. Although β-
blockers are still important drugs for the treatment of angina,
recent MI and patients with LV dysfunction [10, 14, 16–18,
20–22], their efficacy in other indications is under scrutiny.
Controversy has risen about the effectiveness of β-blockers
during non-cardiac surgery [23], although it is still strongly
recommended (class I) to continue β-blockers in patients who
are already receiving these drugs [24].
Limitations
The current analysis is essentially a retrospective analysis of
prospectively collected data and, despite multivariate adjust-
ments and propensity matching, residual confounding can never
be fully eliminated. One might argue that the lack of benefit was
partly caused through bias by indication. Patients on β-blockers
might have been patients with a higher cardiovascular risk as
these agents are often prescribed for residual angina, hyperten-
sion, atrial fibrillation or MI. On the contrary, patients not using
β-blockers were treated with other anti-anginal drugs and had a
slightly higher cardiovascular risk with higher LDL-cholesterol
levels and a little less often anti-platelet therapy. Despite this
apparently higher cardiovascular risk in the reference group, β-
blockers were not associated with benefit in our analysis.
Moreover, our analysis was adjusted for cardiovascular risk as
rigorously as possible, including propensity matching. Another
potential limitation of our analysis is that the sample size might
be too low. Although this may true, we did not observe a trend
towards an effect. In addition, the adequately powered SIGNIFY
trial, which tested a drug with a similar mechanism, did not
demonstrate any beneficial effect despite a large sample size of
19 102 patients [13]. Considering the very low event rate in our
analysis, a trial twice the size of SIGNIFY would be required to
answer this question. Even if β-blockers would appear effective,
the high number needed to treat would most likely not outweigh
the risks and side effects.
Our results should be regarded as hypothesis generating.
Consequently, firm treatment recommendations based only on
the current analysis should be avoided. In addition, we investi-
gated a low-risk population, with good control of their risk fac-
tors, and receiving evidence-based therapy for CAD. The results
for a similar analysis in the general CABG population may be
different. Nevertheless, as evidence to support the continuation
ofβ-blockers after revascularization is currently absent, our anal-
ysis generates the hypothesis that general application of β-
blockers to patients after CABG might not be justified.
Conclusions
β-blocker treatment after CABG in low-risk patients with pre-
served LV systolic function, good control of risk factors, and
receiving evidence-based therapy, was not associated with a
reduced incidence of cardiovascular events or angina during a
median follow-up of 32 months.
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Fig. 5 Risk for primary endpoint
with propensity score and time-
dependent analysis of β-blocker
therapy - Analysis performed
with β-blocker therapy at ran-
domization and β-blocker as a
time-dependent covariate
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